厄贝沙坦与拉西地平对高血压伴左心室肥厚患者左心室重量、C反应蛋白和白介素6影响对比研究  

Therapeutic effects of irbesartan and lacidipine on left ventricular mass,C-reactive protein and interleukin-6 in hypertension patients with left ventricular hypertrophy

作　　者：王瑷萍 

机构地区：[1]四川省成都市新都区中医医院内科,成都610500

出　　处：《中南药学》2013年第12期900-903,共4页Central South Pharmacy

摘　　要：目的考察厄贝沙坦和拉西地平对左心室肥厚高血压患者降低左心室重量指数(LVMI)与C反应蛋白(CRP)和白介素6(IL-6)水平的变化相关性,为临床应用血管紧张素Ⅱ受体阻滞剂治疗左心室肥厚提供理论依据。方法选择2010年5月至2012年5月本院收治的高血压伴左心室肥厚患者,41例给予厄贝沙坦150 mg?d-1,40例给予拉西地平6 mg?d-1,考察2组患者治疗前后LVMI、CRP和IL-6水平变化情况。结果多元回归分析显示,高血压伴左心室肥厚患者LVMI与CRP和IL-6水平显著相关。虽然厄贝沙坦和拉西地平在降低收缩压(SBP)和舒张压(DBP)上效果相同(P>0.05),但厄贝沙坦能有效降低患者LVMI、CRP和IL-6水平(P<0.01);另外还发现,高血压伴左心室肥厚患者应用厄贝沙坦后LVMI下降程度与CRP下降程度(r=0.53,P<0.01)和IL-6下降程度(r=0.72,P<0.01)高度相关。结论 ARB类药物厄贝沙坦具有显著降低高血压伴左心室肥厚患者LVMI、CRP和IL-6水平作用。Objective To inVestigate the effect of irbesartan and lacidipine on decreasing left ventricular mass index （LVMI）, C-reactive protein （CRP） and interleukin-6 （IL-6） in hypertension patients with left ventricular hypertrophy, and provide theoretical base of angiotensin Ⅱ for left ventricular hypertrophy. Methods We selected essential hypertension patients with left ventricular hypertrophy from May 2010 to May 2012 in our hospital： 41 patients were treated with irbe- sartan 150 mg· d^-1 and 40 patients were treated with lacidipine 6 mg· d^-1. LVMI, CRP and IL-6 were detected at the baseline and 6 months respectively. Results Significant correlation between LVMI and CRP as well as between LVMI and IL-6 was observed by multiple regression analysis. LVMI, CRP and IL-6 were significantly decreased （P 〈 0.01）, though treatment reduced SBP and DBP to a similar extent in both groups （P 〉 0.05）. A significant correlation be- tween the decarese in LVMI and CRP （r = 0.53, P 〈 0.01） as well as between LVMI and IL-6 （r = 0.72, P 〈 0.01） was observed. Conclusion Irbesartan has significantly decreased LVMI, CRP and IL-6 in hypertension patients with left ventricular hypertrophy.

关 键 词：厄贝沙坦 高血压 左心室肥厚 拉西地平 

分 类 号：R972.4[医药卫生—药品]